Sale of Saint-Herblon site expected to complete in early 2019
Boehringer Ingelheim has announced the sale of its production site in Saint-Herblon, France, to Dutch company Dopharma.
First announced in October last year, the move follows the presentation of Boehringer’s animal health strategic orientations.
The group confirmed its strategy to focus on advanced and preventative healthcare; Saint-Herblon mainly produces generics and antibiotics for livestock.
Dopharma is an independent, family-owned company that develops, produces and distributes veterinary products for livestock.
Erick Lelouche, president of Boehringer Ingelheim Animal Health in France, said: “I am convinced that this project will offer a solid foundation for the future to the site and its employees. Indeed, we will collaborate with Dopharma Saint-Herblon that will produce some of our specialized products during the coming years.”
The sale is expected to complete by the end of the first quarter of 2019, after the legal and consultation process is finalised.
Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.
